Brendon Neuen's Publications

About Brendon Neuen's Publications

Program Lead, Renal and Metabolic
  • Nephrologist and Director, Kidney Trials, Royal North Shore Hospital
  • Clinical Associate Professor, University of Sydney
  • Conjoint Associate Professor, UNSW Sydney
  • Ph.D. ,
  • MBBS(Hons),
  • MSc(Oxon),
  • FRACP,
  • FASN

  • Kidney failure risk equation and risk of kidney and cardiovascular outcomes in patients with heart failure with reduced ejection fraction: insights from PARADIGM-HF

    European Journal of Heart Failure Date published:

  • Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    The Lancet Date published:

  • Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

    Cardiovascular Diabetology Date published:

  • Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations

    Current Hypertension Reports Date published:

  • The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset

    Journal of the American Society of Nephrology Date published:

  • Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

    Journal of the American Society of Nephrology Date published:

  • The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials

    Diabetes, Obesity and Metabolism Date published:

  • Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

    Journal of the American Heart Association Date published:

  • Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials

    Kidney International Date published:

  • Estimating the population-level kidney benefits of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease in Australian primary care

    Unknown Date published:

  • The prevalence of chronic kidney disease in Australian primary care: analysis of a national general practice dataset

    Unknown Date published:

  • A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine Date published:

  • Empagliflozin in Patients with Chronic Kidney Disease

    New England Journal of Medicine Date published:

  • Biomarkers and personalised medicine in paediatric kidney disease

    The Lancet Child & Adolescent Health Date published: